miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2

Xu, Ke; Liang, Xin; Shen, Ke; Cui, Daling; Zheng, Yang; Xu, Jianhua; Zhang, Fan; Qiu, Yanyan; Li, Qi; Ni, Lei; Liu, Jianwen

doi:10.1042/bj20120386

Cited by 77 publications

(46 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, 16 miRNAs were diversely expressed in HCT116/L-OHP and HCT116 cells. Consistent with microarray data, quantitative RT-PCR analysis showed that miR-297 expression was downregulated in HCT116/L-OHP and HCT-8/VCR cells as compared to their parental cells (23).…”

Section: Mir-297 As Modulator Of Mrp2supporting

confidence: 66%

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

Zhang

Wang

Gupta

et al. 2015

AAPS J

165

114

View full text Add to dashboard Cite

Abstract. The ATP-binding cassette (ABC) transporters are members of a protein superfamily that are known to translocate various substrates across membranes, including metabolic products, lipids and sterols, and xenobiotic drugs. Multidrug resistance proteins (MRPs) belong to the subfamily C in the ABC transporter superfamily. MRPs have been implicated in mediating multidrug resistance by actively extruding chemotherapeutic substrates. Moreover, some MRPs are known to be essential in physiological excretory or regulatory pathways. The importance of MRPs in cancer therapy is also implied by their clinical insights. Modulating the function of MRPs to re-sensitize chemotherapeutic agents in cancer therapy shows great promise in cancer therapy; thus, multiple MRP inhibitors have been developed recently. This review article summarizes the structure, distribution, and physiological as well as pharmacological function of MRP1-MRP9 in cancer chemotherapy. Several novel modulators targeting MRPs in cancer therapy are also discussed.

show abstract

Section: Mir-297 As Modulator Of Mrp2supporting

confidence: 66%

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

Zhang

Wang

Gupta

et al. 2015

AAPS J

165

114

View full text Add to dashboard Cite

show abstract

“…The other related studies almost focused on either 5-fluorouracil (Song et al, 2009;Boni et al, 2010;Valeri et al, 2010;Nishida et al, 2012) or oxaliplatin (Akao et al, 2011;Chai et al, 2011;Xu et al, 2012;Xu et al, 2013). Compared with the studies about one single agent, our work served the clinical practice better.…”

Section: Discussionmentioning

confidence: 88%

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Chen¹,

Xiao²,

Ge³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. FOLFOX is the most common regimen used in the first-line chemotherapy in advanced colorectal cancer, but only half of the patients respond to this regimen and we have almost no clue in predicting resistance in such first-line application. Methods: To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative realtime PCR. Results: 62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis. Among them, 5 (miR-221, miR-222, miR-122, miR-19a, miR-144) were chosen for further validation in an independent population (N=72). Our results indicated serum miR-19a to be significantly up-regulated in resistance-phase serum (p=0.009). The ROC curve analysis showed that the sensitivity of serum miR-19a to discriminate the resistant patients from the response ones was 66.7%, and the specificity was 63.9% when the AUC was 0.679. We additionally observed serum miR-19a had a complementary value for cancer embryonic antigen (CEA). Stratified analysis further revealed that serum miR-19a predicted both intrinsic and acquired drug resistance. Conclusions: Our findings confirmed aberrant expression of serum miR-19a in FOLFOX chemotherapy resistance patients, suggesting serum miR-19a could be a potential molecular biomarker for predicting and monitoring resistance to first-line FOLFOX chemotherapy regimens in advanced colorectal cancer patients.

show abstract

“…Recently, miRNAs have been suggested to play a key role in the development of MDR. 24 Through regulating gene expression, miRNAs can impact on different pathways associated with sensitivity or resistance to chemotherapeutic drugs in various tumors. [13][14][15][16][17] Several miRNAs, such as miR-106a, 25 miR-508-5p 26 and miRNA-19a/b 27 have been reported to play a role in the development of MDR in GC.…”

Section: Discussionmentioning

confidence: 99%

Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance

Danza

Silvestris

Simone

et al. 2016

Cancer Biology & Therapy

View full text Add to dashboard Cite

Despite the search for new therapeutic strategies for gastric cancer (GC), there is much evidence of progression due to resistance to chemotherapy. Multidrug resistance (MDR) is the ability of cancer cells to survive after exposure to chemotherapeutic agents. The involvement of miRNAs in the development of MDR has been well described but miRNAs able to modulate the sensitivity to chemotherapy by regulating hypoxia signaling pathways have not yet been fully addressed in GC. Our aim was to analyze miR-20b, miR-27a and miR-181a expression with respect to (epirubicin/oxaliplatin/capecitabine (EOX)) chemotherapy regimen in a set of GC patients, in order to investigate whether miRNAs deregulation may influence GC MDR also via hypoxia signaling modulation. Cancer biopsy were obtained from 21 untreated HER2 negative advanced GC patients, retrospectively analyzed. All patients received a first-line chemotherapy (EOX) regimen. MirWalk database was used to identify miR-27a, miR-181a and miR-20b target genes. The expression of miRNAs and of HIPK2, HIF1A and MDR1 genes were detected by real-time PCR. HIPK2 localization was assessed by immunohistochemistry. Our data showed the down-regulation of miR-20b, miR-27a, miR-181a concomitantly to higher levels of MDR1, HIF1A and HIPK2 genes in GC patients with a progressive disease respect to those with a disease control rate. Moreover, immunohistochemistry assay highlighted a higher cytoplasmic HIPK2 staining, suggesting a different role for it. We showed that aberrant expression of miR-20b, miR27a and miR-181a was associated with chemotherapeutic response in GC through HIF1A, MDR1 and HIPK2 genes modulation, suggesting a possible novel therapeutic strategy.

show abstract

miR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2

Cited by 77 publications

References 32 publications

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

Multidrug Resistance Proteins (MRPs) and Cancer Therapy

Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases

Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance

Contact Info

Product

Resources

About